RecruitingInterventionalPhase 3

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

NCT ID: NCT07222566Sponsor: PfizerLast updated: 2026-06-04

Summary

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC. * Is not a candidate for complete surgical resection or curative chemoradiotherapy. * Do not have known actionable genomic alterations * Be treatment naïve for advanced or metastatic disease Participants in this study will be assigned to two different parts of the study depending on their type of tumor: participants with squamous NSCLC will be assigned to Part 1, while participants with non-squamous NSCLC will be assigned to Part 2. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups in a blinded fashion: * Part 1 - Arm A or Part 2 - Arm C (Experimental Group): Will receive a new study medicine called PF-08634404 along with a kind of chemotherapy specific to the type of tumor. * Part 1 - Arm B or Part 2 - Arm D (Control Group): Will receive an approved medicine called pembrolizumab along with a kind of chemotherapy specific to the type of tumor. Participants will receive their assigned treatment through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, participants will receive PF-08634404 or Pembrolizumab in combination with chemotherapy followed by maintenance with either PF-08634404 or Pembrolizumab monotherapy (Part 1) or PF-08634404 or Pembrolizumab in combination with a chemotherapeutic drug (Part 2). Participants will continue receiving treatment if it is helping and not experiencing serious side effects. The study will include regular visits for: * Treatment and health checks: while participant continues receiving treatment. * Tests to monitor how cancer responds: every 6 weeks during the first 48 weeks, then every 12 weeks thereafter.

Arms & interventions

BiologicalPF-08634404
Solution for infusion
BiologicalPembrolizumab
Injection for IV use
DrugChemotherapy Regimen 1
Injection for IV use
DrugChemotherapy Regimen 2
Injection for IV use

Outcome measures

Primary

Overall Survival
Overall survival defined as the time from the date of randomization to the date of death due to any cause.
Time frame: Approximately 39 months
Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
Progression-free survival is defined as the time from the date of randomization to the date of the first documentation of objective progressive disease (PD) assessed by BICR per RECIST v1.1, or death due to any cause, whichever occurs first.
Time frame: Approximately 32 months

Secondary

Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by BICR
Time frame: Approximately 32 months
Progression Free Survival as assessed by Investigator
Time frame: Approximately 32 months
Confirmed ORR using RECIST v1.1 as assessed by investigator
Time frame: Approximately 32 months
Duration of Response (DoR) as assessed by BICR
Time frame: Approximately 32 months
Duration of Response (DoR) as assessed by Investigator
Time frame: Approximately 32 months
Number of Participants With Adverse Events (AEs)
Time frame: Through end of study and up to approximately 39 months
Number of Participants With Clinical Laboratory Abnormalities
Time frame: through end of study and up to approximately 39 months
Pharmacokinetics (PK): Serum concentrations of PF-08634404
Time frame: Through end of study and up to approximately 39 months
Incidence of Anti-Drug Antibody (ADA) against PF-08634404.
Time frame: Through end of study and up to approximately 39 months
Mean scores and Change from baseline in the global health status/quality of life (QoL) and physical function scores on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Time frame: Approximately 39 months
Time to definitive deterioration (TTdD) in in the global health status/QoL and physical function scores on the EORTC QLQ-C30
Time frame: Approximately 39 months
Mean scores and Change from Baseline in dyspnea, cough, and chest pain scores on the EORTC Quality of Life Cancer Questionnaire - Lung Cancer 13 QLQ-LC13
Time frame: Approximately 39 months
TTdD in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13
Time frame: Approximately 39 months

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No

Inclusion Criteria: * 18 years of age or older at screening. * Have pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV)squamous or non-squamous NSCLC and not be a candidate for complete surgical resection and curative concurrent/sequential chemoradiotherapy (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer Tumor, lymph nodes, metastasis (TNM) staging system). * Have tumor tissue available, either paraffin block or slides from a core, excisional or fine needle biopsy * PD-L1 status available based on local testing results * Measurable disease based on RECIST v1.1 per investigator. * Eastern Cooperative Oncology Group performance status (ECOG) score of 0 or 1 * Expected survival ≥12 weeks Exclusion Criteria: * Participants with known actionable genomic alteration (AGAs), including estimated glomerular filtration rate (EGFR), anaplastic lymphoma kinase (ALK), Repressor of Silencing 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), rearranged during transfection (RET), and mesenchymal-epithelial transition (MET), for which there are available first-line therapies per local standard-of-care (SOC) are ineligible. Documented negative results for EGFR, ALK, and ROS1 AGAs are required for participants with non-squamous histology. * Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be eligible. Clinically inactive brain metastases of longest diameter \< 1 cm are permitted. * Participants with clinically significant risk of hemorrhage or fistula are excluded. * Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. * Unresolved toxicities from prior anti-tumor therapy, that did not recover to NCI CTCAE v5.0 Grade 0 or 1. * Known to have a history of a severe allergy to any component of the study intervention, or a history of severe allergic reaction to chimeric or humanized antibody. * History of allogeneic organ / hematopoietic stem cell transplantation. * Participants with any of the following respiratory conditions: * Evidence of noninfectious or drug-induced interstitial lung disease (ILD) or pneumonitis * Grade ≥3 pulmonary disease unrelated to underlying malignancy * History of uncontrolled comorbidities within 6 months prior to the first dose including uncontrolled cardiac and cerebrovascular conditions, hypertension, diabetes, significant vascular disease or arterial/severe venous thromboembolic events. * Major surgery \< 4 weeks or minor surgery \< 3 days prior to first dose of study intervention. * History of severe bleeding tendency or coagulation dysfunction * History of esophageal varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose. * Participants with acute, chronic or symptomatic infections including participants positive for active HIV, hepatitis B virus (HBV), or Hepatitis C virus (HCV). * Participants with history of immunodeficiency * Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior (in the past 5 years) or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study. * Previous systemic anti-tumor therapy including: 1. Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC. 2. Previous treatment with immunotherapy 3. Prior radiotherapy \> 30 Gy to the lung \< 6 months of first dose of study intervention 4. Palliative local therapy \< 2 weeks before the first dose of study intervention; 5. Non-specific immunomodulatory therapy \< 2 weeks before the first dose. 6. Prior systemic anti-angiogenic therapy * Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, adverse events from prior immunotherapy not improved to Grade 1 before screening, or required treatment with systemic immunosuppressive therapy. * Prior and concomitant therapy: 1. therapeutic oral or parenteral anticoagulants or thrombolytic agents \< 10 days to the first dose. 2. chronic antiplatelet therapy \<7 days to randomization. 3. live or attenuated live vaccine \< 4 weeks to the first dose. 4. current high-dose systemic corticosteroids. 5. prohibited concomitant medication(s) \< 21 days to the first dose. * Breastfeeding participants, participants of childbearing potential, and male participants who are unwilling to follow contraceptive measures.

Study locations (184)

Pioneer Research Center

Bullhead City, Arizona, 86442

Recruiting

Ironwood Cancer & Research Centers

Chandler, Arizona, 85224

Recruiting

Ironwood Cancer & Research Centers

Gilbert, Arizona, 85297

Recruiting

Ironwood Cancer & Research Centers

Glendale, Arizona, 85306

Recruiting

Ironwood Cancer & Research Centers

Goodyear, Arizona, 85395

Recruiting

Ironwood Cancer & Research Centers

Mesa, Arizona, 85202

Recruiting

Ironwood Cancer & Research Centers

Mesa, Arizona, 85206

Recruiting

Ironwood Cancer & Research Centers

Phoenix, Arizona, 85028

Recruiting

Ironwood Cancer & Research Centers

Scottsdale, Arizona, 85260

Recruiting

Highlands Oncology Group

Fayetteville, Arkansas, 72703

Recruiting

Highlands Oncology Group

Rogers, Arkansas, 72758

Recruiting

Highlands Oncology Group

Springdale, Arkansas, 72762

Recruiting

Los Angeles Cancer Network - Anaheim

Anaheim, California, 92805

Recruiting

Los Angeles Cancer Network - Fountain Valley

Fountain Valley, California, 92708

Recruiting

Memorial Care Orange Coast Medical Center Attn

Fountain Valley, California, 92708

Recruiting

OC Blood and Cancer Care

Fountain Valley, California, 92708

Recruiting

Orange Coast Memorial Medical Center

Fountain Valley, California, 92708

Recruiting

Memorial Care Saddleback Medical Center Attn

Laguna Hills, California, 92653

Recruiting

Stockton Hematology Oncology Medical Group

Lodi, California, 95242

Not Yet Recruiting

Memorial Care Long Beach Medical Center

Long Beach, California, 90806

Recruiting

Los Angeles Cancer Network - Good Samaritan

Los Angeles, California, 90017

Recruiting

Stockton Hematology Oncology Medical Group

Manteca, California, 95336

Not Yet Recruiting

Stockton Hematology Oncology Medical Group

Modesto, California, 95350

Not Yet Recruiting

Los Angeles Cancer Network - Riverside

Riverside, California, 92501

Recruiting

Sansum Clinic

Santa Barbara, California, 93105

Recruiting

Sansum Clinic

Solvang, California, 93463

Recruiting

Stockton Hematology Oncology Group

Stockton, California, 95204

Not Yet Recruiting

Stockton Hematology Oncology Medical Group

Tracy, California, 95377

Not Yet Recruiting

Los Angeles Cancer Network - Valley Presbyterian

Van Nuys, California, 91405

Recruiting

Florida Cancer Specialists

Bonita Springs, Florida, 34135

Recruiting

Florida Cancer Specialists

Bradenton, Florida, 34211

Recruiting

Florida Cancer Specialists

Cape Coral, Florida, 33909

Recruiting

Florida Cancer Specialists

Clearwater, Florida, 33761

Recruiting

BRCR Global- Coral Springs

Coral Springs, Florida, 33065

Recruiting

Florida Cancer Specialists

Daytona Beach, Florida, 32117

Recruiting

Cancer Specialists of North Florida

Fleming Island, Florida, 32003

Recruiting

Florida Cancer Specialists

Fleming Island, Florida, 32003

Recruiting

Helios Clinical Research

Fort Lauderdale, Florida, 33316

Recruiting

Florida Cancer Specialists - South

Fort Myers, Florida, 33901

Recruiting

Florida Cancer Specialists

Fort Myers, Florida, 33905

Recruiting

Florida Cancer Specialists

Fort Myers, Florida, 33908

Recruiting

Florida Cancer Specialists

Gainesville, Florida, 32605

Recruiting

Cancer Specialists of North Florida

Jacksonville, Florida, 32204

Recruiting

Cancer Specialists of North Florida

Jacksonville, Florida, 32218

Recruiting

Cancer Specialists of North Florida

Jacksonville, Florida, 32256

Recruiting

Cancer Specialists of North Florida

Jacksonville, Florida, 32258

Recruiting

Florida Cancer Specialists

Largo, Florida, 33770

Recruiting

Florida Cancer Specialists

Lecanto, Florida, 34461

Recruiting

Florida Cancer Specialists

N. Venice, Florida, 34275

Recruiting

Florida Cancer Specialists

Naples, Florida, 34102

Recruiting

Cancer Specialists of North Florida

Neptune Beach, Florida, 32266

Recruiting

Florida Cancer Specialists

Ocala, Florida, 34474

Recruiting

Florida Cancer Specialists

Orange City, Florida, 32763

Recruiting

Mid Florida Hematology and Oncology Center

Orange City, Florida, 32763

Recruiting

Florida Cancer Specialists

Orlando, Florida, 32806

Recruiting

Orlando Health Ambulatory Care Center

Orlando, Florida, 32806

Not Yet Recruiting

Orlando Health Cancer Institute

Orlando, Florida, 32806

Not Yet Recruiting

Orlando Health Orlando Regional Medical Center

Orlando, Florida, 32806

Not Yet Recruiting

Cancer Care Centers of Brevard, Inc.

Palm Bay, Florida, 32901

Recruiting

Florida Cancer Specialists

Palm Beach Gardens, Florida, 33410

Recruiting

Florida Cancer Specialists

Port Charlotte, Florida, 33980

Recruiting

Hematology Oncology Associates of the Treasure Coast

Port Saint Lucie, Florida, 34952

Recruiting

Cancer Specialists of North Florida

Saint Augustine, Florida, 32086

Recruiting

Florida Cancer Specialists

Sarasota, Florida, 34236

Recruiting

Florida Cancer Specialists

Sebring, Florida, 33870

Recruiting

Florida Cancer Specialists

St. Petersburg, Florida, 33701

Recruiting

Florida Cancer Specialists

St. Petersburg, Florida, 33705

Recruiting

Florida Cancer Specialists

Tallahassee, Florida, 32308

Recruiting

BRCR Medical Center Inc.

Tamarac, Florida, 33321

Recruiting

Florida Cancer Specialists

Tampa, Florida, 33607

Recruiting

Florida Cancer Specialists

Tavares, Florida, 32778

Recruiting

Florida Cancer Specialists

The Villages, Florida, 32159

Recruiting

Florida Cancer Specialists

Trinity, Florida, 34655

Recruiting

Florida Cancer Specialists

Wellington, Florida, 33414

Recruiting

Florida Cancer Specialists - East

West Palm Beach, Florida, 33401

Recruiting

Florida Cancer Specialists

Winter Park, Florida, 32789

Recruiting

Illinois Cancer Specialists

Arlington Heights, Illinois, 60005

Recruiting

Illinois CancerCare - Bloomington

Bloomington, Illinois, 61704

Recruiting

University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center)

Chicago, Illinois, 60612

Not Yet Recruiting

University of Illinois Hospital and Health Sciences System

Chicago, Illinois, 60612

Not Yet Recruiting

Illinois CancerCare - Galesburg

Galesburg, Illinois, 61401

Recruiting

Hope and Healing Cancer Services

Hinsdale, Illinois, 60521

Recruiting

Hope and Healing Cancer Services

New Lenox, Illinois, 60451

Recruiting

Illinois CancerCare-Ottawa-Fox River Cancer Center

Ottawa, Illinois, 61350

Recruiting

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

Recruiting

Illinois CancerCare, P.C.

Peoria, Illinois, 61615

Recruiting

Illinois CancerCare-Peru - Valley Regional Cancer Center

Peru, Illinois, 61354

Recruiting

Illinois CancerCare-Washington

Washington, Illinois, 61571

Recruiting

Pontchartrain Cancer Center

Covington, Louisiana, 70433

Not Yet Recruiting

Pontchartrain Cancer Center

Hammond, Louisiana, 70403

Not Yet Recruiting

Maryland Oncology Hematology, P.A.

Annapolis, Maryland, 21401

Recruiting

Maryland Oncology Hematology, P.A.

Bethesda, Maryland, 20817

Recruiting

Maryland Oncology Hematology, P.A.

Brandywine, Maryland, 20613

Recruiting

Maryland Oncology Hematology - Columbia

Columbia, Maryland, 21044

Recruiting

Maryland Oncology Hematology, P.A.

Germantown, Maryland, 20876

Recruiting

Maryland Oncology Hematology, P.A.

Largo, Maryland, 20774

Recruiting

Maryland Oncology Hematology, P.A.

Rockville, Maryland, 20850

Recruiting

Maryland Oncology Hematology, P.A.

Silver Spring, Maryland, 20904

Recruiting

Minnesota Oncology Hematology, P.A.

Burnsville, Minnesota, 55337

Recruiting

Minnesota Oncology Hematology, P.A.

Chaska, Minnesota, 55318

Recruiting

Minnesota Oncology Hematology, P.A.

Coon Rapids, Minnesota, 55433

Recruiting

Minnesota Oncology Hematology, P.A.

Edina, Minnesota, 55435

Recruiting

Minnesota Oncology Hematology, P.A.

Maple Grove, Minnesota, 55369

Recruiting

Minnesota Oncology Hematology, P.A.

Maplewood, Minnesota, 55109

Recruiting

Minnesota Oncology Hematology, P.A.

Woodbury, Minnesota, 55125

Recruiting

NHO Revive Research Institute, LLC

Lincoln, Nebraska, 68506

Recruiting

NHO Support Center

Lincoln, Nebraska, 68506

Recruiting

Cancer Partners of Nebraska

Lincoln, Nebraska, 68516

Recruiting

New York Oncology Hematology

Albany, New York, 12206

Recruiting

New York Oncology Hematology

Clifton Park, New York, 12065

Recruiting

Hematology Oncology Associates of Rockland

Nyack, New York, 10960

Recruiting

Carolina Cancer Research Center

Wilson, North Carolina, 27893

Recruiting

Oncology Hematology Care Clinical Trials

Cincinnati, Ohio, 45211

Recruiting

Oncology Hematology Care Clinical Trials

Cincinnati, Ohio, 45242

Recruiting

Oncology Hematology Care Clinical Trials

Cincinnati, Ohio, 45245

Recruiting

Oncology Hematology Care Clinical Trials

Fairfield, Ohio, 45014

Recruiting

Northwest Cancer Specialists, P.C

Happy Valley, Oregon, 97015

Recruiting

Northwest Cancer Specialists, P.C.

Portland, Oregon, 97227

Recruiting

Northwest Cancer Specialists, P.C

Tigard, Oregon, 97223

Recruiting

Tennessee Oncology, PLLC - Chattanooga Downtown

Chattanooga, Tennessee, 37403

Recruiting

Tennessee Oncology, PLLC - Chattanooga - Medical Park II

Chattanooga, Tennessee, 37404

Recruiting

Tennessee Oncology, PLLC - Franklin

Franklin, Tennessee, 37067

Recruiting

Tennessee Oncology, PLLC - Gallatin

Gallatin, Tennessee, 37066

Recruiting

Tennessee Cancer Specialists Dowell Springs location

Knoxville, Tennessee, 37909

Recruiting

Tennessee Cancer Specialists - Parkwest Location

Knoxville, Tennessee, 37932

Recruiting

Tennessee Oncology, PLLC - Lebanon

Lebanon, Tennessee, 37090

Recruiting

Tennesseee Oncology, PLLC - Mount Juliet

Mount Juliet, Tennessee, 37122

Recruiting

Tennessee Oncology, PLLC - Murfreesboro

Murfreesboro, Tennessee, 37129

Recruiting

SCRI Oncology Partners

Nashville, Tennessee, 37203

Recruiting

Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology

Nashville, Tennessee, 37203

Recruiting

Tennessee Oncology, PLLC - Saint Thomas West

Nashville, Tennessee, 37205

Recruiting

Tennessee Oncology, PLLC -Shelbyville

Shelbyville, Tennessee, 37160

Recruiting

Texas Oncology - West Texas

Abilene, Texas, 79606

Recruiting

Texas Oncology - Northeast Texas

Allen, Texas, 75013

Recruiting

Texas Oncology - West Texas

Amarillo, Texas, 79124

Recruiting

Texas Oncology - DFW

Arlington, Texas, 76012

Not Yet Recruiting

Texas Oncology - DFW

Arlington, Texas, 76014

Not Yet Recruiting

Texas Oncology - Central/South Texas

Austin, Texas, 78758

Recruiting

Texas Oncology - Gulf Coast

Beaumont, Texas, 77702

Recruiting

Texas Oncology - DFW

Bedford, Texas, 76022

Not Yet Recruiting

Texas Oncology - DFW

Dallas, Texas, 75203

Not Yet Recruiting

Texas Oncology - DFW

Dallas, Texas, 75230

Not Yet Recruiting

Texas Oncology - DFW

Dallas, Texas, 75231

Not Yet Recruiting

Texas Oncology - DFW

Dallas, Texas, 75237

Not Yet Recruiting

Texas Oncology - DFW

Dallas, Texas, 75246

Not Yet Recruiting

Texas Oncology - Northeast Texas

Denison, Texas, 75020

Recruiting

Texas Oncology - Northeast Texas

Denton, Texas, 76201

Recruiting

Texas Oncology - West Texas

El Paso, Texas, 79902

Recruiting

Texas Oncology - West Texas

El Paso, Texas, 79915

Recruiting

Texas Oncology - West Texas

El Paso, Texas, 79938

Recruiting

Texas Oncology - Northeast Texas

Flower Mound, Texas, 75028

Recruiting

Texas Oncology - DFW

Fort Worth, Texas, 76104

Not Yet Recruiting

Texas Oncology - DFW

Grapevine, Texas, 76051

Not Yet Recruiting

Texas Oncology - Central/South Texas

Harlingen, Texas, 78550

Recruiting

Texas Oncology - Gulf Coast

Houston, Texas, 77024

Recruiting

Texas Oncology - Gulf Coast

Houston, Texas, 77054

Recruiting

Texas Oncology - Gulf Coast

Houston, Texas, 77070

Recruiting

Texas Oncology - Gulf Coast

Humble, Texas, 77338

Recruiting

US Oncology Investigational Products Center (IPC)

Irving, Texas, 75063

Recruiting

US Oncology Investigational Products Center

Irving, Texas, 75063

Recruiting

Texas Oncology - Northeast Texas

Lewisville, Texas, 75056

Recruiting

Texas Oncology - Northeast Texas

Longview, Texas, 75601

Recruiting

Texas Oncology - Central/South Texas

McAllen, Texas, 78503

Recruiting

Texas Oncology - Northeast Texas

McKinney, Texas, 75071

Recruiting

Texas Oncology - West Texas

Midland, Texas, 79701

Recruiting

Texas Oncology - West Texas

Odessa, Texas, 79761

Recruiting

Texas Oncology - Northeast Texas

Palestine, Texas, 75801

Recruiting

Texas Oncology - Northeast Texas

Paris, Texas, 75460

Recruiting

Texas Oncology - Gulf Coast

Pearland, Texas, 77584

Recruiting

Texas Oncology - DFW

Plano, Texas, 75075

Not Yet Recruiting

Texas Oncology - DFW

Plano, Texas, 75093

Not Yet Recruiting

Texas Oncology - Gulf Coast

Sugar Land, Texas, 77479

Recruiting

Texas Oncology - Gulf Coast

The Woodlands, Texas, 77380

Recruiting

Texas Oncology - Northeast Texas

Tyler, Texas, 75702

Recruiting

Texas Oncology - Central/South Texas

Waco, Texas, 76712

Recruiting

Texas Oncology - Gulf Coast

Webster, Texas, 77598

Recruiting

Texas Oncology - Central/South Texas

Weslaco, Texas, 78596

Recruiting

Texas Oncology - West Texas

Wichita Falls, Texas, 76310

Recruiting

UVA Comprehensive Cancer Center

Charlottesville, Virginia, 22903

Not Yet Recruiting

UVA Health Fontaine Research Park

Charlottesville, Virginia, 22903

Not Yet Recruiting

University of Virginia

Charlottesville, Virginia, 22908

Not Yet Recruiting

UVA Health Cancer Care Pantops

Charlottesville, Virginia, 22911

Not Yet Recruiting

Northwest Cancer Specialists, P.C.

Vancouver, Washington, 98684

Recruiting

Minnesota Oncology Hematology, P.A.

Hudson, Wisconsin, 54016

Recruiting